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Abstract
Nonalcoholic fatty liver disease (NAFLD) includes various hepatic pathologies ranging from hepatic steatosis to non-
alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Estrogen provides a protective effect on the development of NAFLD
in women. Therefore, postmenopausal women have a higher risk of developing NAFLD. Hepatic steatosis is an early stage of
fatty liver disease. Steatosis can develop to the aggressive stages (nonalcoholic steatohepatitis, fibrosis and cirrhosis).
Currently, there is no specific drug to prevent/treat these liver diseases. In this study, we found that white button
mushroom (WBM), Agaricus Bisporus, has protective effects against liver steatosis in ovariectomized (OVX) mice (a model of
postmenopausal women). OVX mice were fed a high fat diet supplemented with WBM powder. We found that dietary WBM
intake significantly lowered liver weight and hepatic injury markers in OVX mice. Pathological examination of liver tissue
showed less fat accumulation in the livers of mice on WBM diet; moreover, these animals had improved glucose clearance
ability. Microarray analysis revealed that genes related to the fatty acid biosynthesis pathway, particularly the genes for fatty
acid synthetase (Fas) and fatty acid elongase 6 (Elovl6), were down-regulated in the liver of mushroom-fed mice. In vitro
mechanistic studies using the HepG2 cell line showed that down-regulation of the expression of FAS and ELOVL6 by WBM
extract was through inhibition of Liver X receptor (LXR) signaling and its downstream transcriptional factor SREBP1c. These
results suggest that WBM is protective against hepatic steatosis and NAFLD in OVX mice as a model for postmenopausal
women.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
liver disease in adults in developed countries [1]. It is characterized
by excessive hepatic lipid accumulation and is not related to
alcohol use. NAFLD includes various hepatic pathologies ranging
from hepatic steatosis to non-alcoholic steatohepatitis (NASH),
fibrosis and cirrhosis. NAFLD is associated with metabolic
syndrome, which has been characterized by obesity, type 2
diabetes, arterial hypertension, and hypertriglyceridemia in mice
[1,2]. Also, cirrhosis is a risk factor for the development of portal
hypertension, hepatocellular carcinoma and liver failure [1]. It has
been suggested that estrogen provides a protective effect on the
development of NAFLD in women [3]. Therefore, postmeno-
pausal women have a higher risk of developing NAFLD due to a
lower level of circulating estrogen [3]. Due to an increased average
life span, present generations of women can expect to spend at
least a third of their lives in the postmenopausal state [4]. Dietary
and lifestyle guidelines to reduce overall body weight may help
avoid NAFLD, however, there are no specific drugs to treat this
liver disease [5].
Mushroom has been reported to have many bioactive
compounds (mycochemicals) [6,7]. It has been reported that
components of various species of mushrooms have a positive
impact on human health through effects on the immune system,
lipid levels in blood and liver, and tumor growth [6,8,9,10,11]. It is
reported that several species of mushroom, including white button
mushroom (WBM) (Agaricus bisporus), oyster mushroom (Pleurotus
Ostreatus) and Shiitake (Lentinus edodes), reduce the cholesterol
level in serum and/or liver [8,12,13]. Furthermore, recently
mukitake mushroom (Panellus serotinus) was reported to alleviate
nonalcoholic fatty liver disease in db/db mice [9]. However, the
exact mechanisms to prevent NAFLD and its active components
have not been identified yet. WBM constitutes 90% of the total
mushrooms consumed in the US. Nevertheless, information is
limited on health benefits of WBM [6]. Previous data in our
laboratory showed that WBM had a significant inhibitory effect on
the growth of the estrogen receptor (ER)-positive, aromatase-
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through the inhibition of aromatase, the enzyme that catalyzes the
formation of estrogen from androgen. In addition, WBM intake
inhibited MCF-7aro tumor growth in nude mice. Conjugated
linoleic acid was identified as an active component with anti-
aromatase activity [10]. Based on our preclinical data, a clinical
trial of WBM is currently underway in postmenopausal, ER-
positive breast cancer survivors to determine whether clinically
detectable estrogen suppression can be achieved [14]. Although
mukitake mushroom was reported to improve NAFLD, due to the
observed anti-aromatase effect of WBM, there were clinical
concerns that the resulting decrease in estrogen in women could
exacerbate NAFLD in postmenopausal women. However, in a
recent preclinical study we found that ovariectomized (OVX) mice
fed a high fat diet with WBM powder (HFD+WBM) had relatively
normal livers in terms of the size and appearance compared to
mice fed a high fat diet (HFD) only. These observations, taken
together with previous reports that show positive impacts of WBM
intake on human health, led us to hypothesize that WBM may
improve liver steatosis in postmenopausal women. To support our
hypothesis, we also examined the effect of WBM on liver steatosis
in the OVX mouse model and fatty acid metabolism in human
hepatoma HepG2 cell line. The objective of the study was to gain
insight into how dietary supplementation of WBM can prevent
and/or ameliorate NAFLD in postmenopausal women.
Materials and Methods
Preparation of WBM diet
WBM were freeze-dried to steady moisture content, and then
milled through a fine mesh. Microbiological and other analytical
measurements were performed on pooled samples/batches to
assure the quality of the WBM powder for research. The control
HFD (45% (wt/wt) fat diet) and the HFD modified to contain
freeze-dried WBM powder were produced and purchased from
Research Diets, Inc (New Brunswick, NJ) (Table 1). For a proof-of-
concept study to provide definitive data, the diet was composed of
120 g of WBM powder/kg of HFD, a similar dose as used
previously to evaluate the effect of Mukitake mushroom diet for
NAFLD [9]. Moreover, this therapeutic dose of WBM was shown
to suppress estrogen-dependent and aromatase-positive breast
cancer growth in our laboratory, using a nude mice model [10].
Mouse experimental design
All animal research procedures were approved by the
institutional animal care and use committee (IACUC) at City of
Hope for assessment and accreditation of laboratory animal care,
and were in accordance with NIH guidelines. Breeding stock strain
C57Bl/6J was obtained from Jackson Labs. All animals were
housed at the City of Hope Animal Resources Center in ventilated
cage racks, had free access to water and were maintained on a
12 h light/dark cycle. All institutional guidelines for animal care
and use were followed. The protocol for this study was approved
by IACUC (protocol number: 08047).
To create a mouse model of postmenopausal women, seven-
week old, female C57B1/6J mice were ovariectomized (OVX,
n=16). These OVX mice only produce estrogen from extra-
gonadal sites and are used extensively as a model of postmeno-
pausal women [4,15]. Control mice (sham, n=16) were subjected
to sham operation survival surgery. The sham mice were subjected
to the same general surgical procedure as OVX mice, except the
removal of the ovaries. Mice were then divided into two dietary
groups, with eight mice per group: HFD or HFD+WBM. The
diets were started one week after surgery and continued for 3
months. The pair feeding design was used to control food intake.
Food was weighed daily, and the control group given the same
amount of food (by weight) one day later as the WBM group to
ensure identical caloric intake between groups. At the conclusion
of the experiment, mice were fasted for 4 hours before sacrifice.
Blood of the mice was collected by cardiac puncture. After mice
were euthanized, liver samples were collected.
Pathological analysis
Livers were harvested from the mice and the wet weights
measured. The tissues were fixed with 10% formalin overnight
and then embedded in paraffin. Five-micrometer sections were cut
and stained with hematoxylin and eosin, and examined by light
microscope.
Liver enzyme measurement
Blood samples were collected at the end of each experiment via
cardiac puncture and centrifuged at 4000 rpm for 10 minutes to
obtain serum. Serum alanine aminotransferase (ALT) levels were
measured by Antech diagnostics company (Irvine, CA).
Glucose tolerance test
Glucose tolerance tests were performed 2 months after starting
the treatment diet. The mice were fasted with free access to
drinking water for 18 hours prior to the test. Baseline glucose
levels were recorded for each mouse. The mice were challenged
with a 1.5 mg glucose/g body weight glucose load. The glucose
levels pre, 30, 60, 120 and 180 min post-injection were measured
using a glucometer (Bayer, Germany).
Microarray analysis
For microarray analysis, total RNA was extracted from four
liver specimens from OVX mice fed with HFD or from OVX
mice fed with HFD+WBM using TRIzol reagent (Invitrogen,
Carlsbad, CA). Synthesis and labeling of complementaryRNA
(cRNA) targets, hybridization of GeneChips, and signal detection
Table 1. Composition of experimental diets.
Ingredient HF HF-WBM
(g/kg diet)
Casein 165 165
L-Cystine 3 3
Corn Starch 224 171
Maltodextrin 10 132 132
Sucrose 100 100
Cellulose, BW200 50 50
Corn Oil 70 70
Lard 173 173
t-Butylhydroquinone 0.014 0.014
Mineral Mix S10022G 35 35
Vitamin Mix V10037 10 10
Choline Bitartrate 2.5 2.5
White button mushroom powder
a 01 2 0
Powder was mixed to a modified AIN-93G diet enriched in fat (HF).
aCarbohydrate: 43.30%, fiber: 13.20% protein: 28.80%, fat: 4.50%.
doi:10.1371/journal.pone.0026654.t001
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Briefly, The Affymetrix Mouse Gene 1.0 ST Array (Affymetrix,
Santa Clara, CA) was used for microarray gene expression
profiles. The microarray was carried out using Ambion’s WT
Expression kit (Life Technologies, Carlsbad, CA) and Affymetrix’s
GeneChip Terminal labeling system. Briefly, 100 ng of total RNA
was used to start the first strand cDNA synthesis using an
engineered random primer plus polyT7 promoter. After the 2
nd
strand cDNA synthesis, the antisense cRNA (in vitro transcription)
was carried using T7 RNA polymerase. Then, 10 mg of cRNA was
used to start the 2
nd cycle of cDNA synthesis using random
primers plus dUTP and dNTP mix. The single-strand cDNA was
fragmented and then end-labeled with biotinylated nucleotides in
the presence of terminal deoxynucleotidyl transferase (TdT) using
Affymetrix WT Terminal Labeling kit. Five mg of labeled single-
stranded cDNA was hybridized with Affymetrix Mouse Gene 1.0
ST array using the standard procedure as described previously
[16] and the array was scanned using Affymetrix GeneChip
Scanner 3000 7G.
Statistical processing of Microarray data
Raw intensity measurements of all probe sets were corrected
for background, normalized and converted into transcript-level
expression measurements by using the IterPlier method in
Affymetrix Power Tools (version 1.8.6). Quality assessment and
statistical analysis of gene expression data were performed using
the R/Bioconductor packages. To ensure the high quality of the
microarray process, a set of quality assessment steps implemented
in Bioconductor package Array Tools (http://www.bioconductor.
org/packages/release/bioc/html/ArrayTools.html) were applied
to the data. ArryTools was then used to identify the genes
differentially expressed between OVX and OVX+WBM samples.
Genes with significantly differentially expression were selected by
use of cutoffs of p-value of 0.05 and 2-fold change in the level of
expression. The genes showing altered expression were catego-
rized and further investigated by enrichment analysis on the basis
of their cellular components, biological processes, molecular
functions, and canonical pathways using the Ingenuity Pathways
Analysis (IPA)(Version 9.0)(Ingenuity) software. Data is MIAME
compliant and the raw data has been deposited in NCBI Gene
Expression Omnibus (GEO) with accession number of
GSE31854.
Ingenuity Pathway Analysis (IPA)
IPA is a Web-based software program that identifies the
biological functions, pathways, and mechanisms most relevant to a
given data set of genes. Information on individual genes is drawn
from a large knowledge base of biological networks created from
millions of publications, and the networks are drawn by the
Functional Analysis feature of IPA based on the connectivity of the
genes. To obtain a comprehensive view for the differentially
expressed genes, core analysis was performed including network
generation, functional analysis and canonical pathway analysis on
the filtered (|Fold Change|.2, P,0.05) genes.
Cell Culture
HepG2 cells were obtained from the American Type Culture
Collection (ATCC) and grown in MEM containing 10% charcoal
dextran treated fetal bovine serum (CD-FBS) in the presence of
100 U/ml penicillin and 0.1 g/l streptomycin. Cells were
incubated at 37uC with 95% air and 5% carbon dioxide. All cells
were kept below passage 20 and used in experiments during the
linear phase of growth.
Real-time PCR
The analysis was performed using RNA extracted from liver
tissue (described under ‘‘Microarray analysis’’) and from HepG2
cells. For cell culture studies, HepG2 cells were plated in 60 mm
dishes at a density of 8610
5 cells/dish and treated with either
DMSO or WBM extract. Twenty-four hours after treatment, the
cells were collected for analysis of gene expression. Cells were
washed with PBS, and Trizol reagent was used for total RNA
isolation (Invitrogen). cDNA was synthesized with isolated RNA
using reverse transcriptase III (Invitrogen). Real time PCR primers
were as follows: mouse b-actin, 5’-CATTGCTGACAGGATG-
CAGAAGAAG-3’ and 5’-CCTGCTTGCTGATCCACATCTG-
CT-3’; mouse fatty acid synthetase (Fas), 5’-TGGGTTCTAGC-
CAGCAGAGT-3’ and 5’-AGACCGTTATGCCCAGACAG-3’;
mouse fatty acid elongase (Elovl6), 5’-ACAATGGACCTGTCAG-
CAAA-3’ and 5’-GTACCAGTGCAGGAAGATCAGT-3’; hu-
man b-actin, 5’-CACCAACTGGGACGACAT-3’ and 5’-GCA-
CAGCCTGGATAGCAA-3’; human ELOVL6, 5’-ACAATGG-
ACCTGTCAGCAAA-3’ and 5’-ATACCAGTGCAGGAAGAT-
CAG-3’; human sterol regulatory element-binding protein 1
(SREBP1c), 5’-CCATGGATTGCACTTTCGAAGA-3’ and 5’-
GCTCAATGTGGCAGGAGGTG-3’; and human FAS, 5’-A-
GGCTGAGACGGAGGCCATA-3’ and 5’-AAAGCTCAGCT-
CCTGGAGGT-3’. Reactions were run in triplicate on the iCycler
iQ5 real time PCR detection system (Bio-Rad, Hercules, CA), and
results were analyzed with the iQ5 software.
Western blotting
HepG2 cells were seeded in 60 mm dishes at a density of
8610
5 cells/dish and treated with either vehicle control, Liver X
receptor (LXR) agonist T0901317 (Cayman CHEMICAL, Ann
Arbor, MI) (10 mM) or various concentrations of WBM extract for
48 hours. Proteins were isolated from HepG2 cells using passive
lysis buffer (Promega, Fitchburg, WI). Liver tissues were collected
at the end of experiment and then lysed using T-PER Tissue
Protein Extraction Reagent (Thermo Scientific, Waltham, MA)
according to the manufacturer’s protocol. Briefly, liver tissues were
weighed and homogenized in T-PER reagent containing protease
and phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)
using the T25 Basic tissue homogenizer (IKA Works, Inc.,
Wilmington, NC). For both tissue and cell lysis, samples were
centrifuged at 10,000 X g for 5 minutes and the supernatant run
on a 12% acrylamide gel, transferred to a nitrocellulose membrane
and probed with antibodies to FAS (Abcam, Cambridge, MA),
ELOVL6 (Abnova, Taipei City, Taiwan) or b-actin (Cell Signaling
Technology, Inc., Danvers, MA). Bands were visualized via
chemiluminescence using HRP-conjugated secondary antibodies
and quantified using BioRad Quantity One software.
Reporter gene assay
HepG2 cells were plated in 24-well plates at a density of
8610
5 cells/well and treated with either DMSO or WBM extract.
To evaluate WBM effects on LXR activity, HepG2 cells were
transiently transfected with the pCMX-VP16-hLXRa and LXR-
responsive rCYP7A-DR-4x3-tk-LUC using the Lipofectamine
Plus reagent system (Invitrogen) according to the manufacturer’s
protocol. 24 hours post-transfection, cells were treated with
compound T0901317 (10 mM) alone or in combination with
WBM extract (1, 2 and 5 ml/ml) for 24 hours. For evaluation of
WBM effects on ER activity, HepG2 cells were transiently
transfected with the pSG5-ER and pGL3 (ERE) 3-Luc using the
Lipofectamine Plus reagent system (Invitrogen). 24 hours post-
transfection, cells were treated with 17b-estradiol (E2) (Sigma-
Aldrich) (0.1 nM) or with WBM extract (5 and 10 ml/ml) for
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luciferase activity assayed on a TD 20/20 luminometer (Turner
Designs, Sunnyvale, CA). Protein concentration was assayed using
the BCA Assay (Thermo scientific). Data is expressed as relative
luciferase unit/protein content.
Production of Crude Mushroom Extract
As a control against the WBM investigation, we also did an
analysis of other types of mushroom in a Mushroom Extract form.
Mushroom extract was produced by chopping 60 g of fresh
mushroom (WBM, shiitake mushroom (Lentinus edodes), enoki
mushroom (Flammulina velutipes), or oyster mushroom (Pleurotus
ostreatus)) and boiling the chopped mushroom in 500 ml water. The
broth was filtered and centrifuged at 5,000 rpm for 30 minutes.
Supernatant was rotor-evaporated until the final volume was 6 ml.
Fractionation of WBM extract
Crude WBM extract was loaded to 5 g/60 ml capacity
polyamide columns (Discovery DPA-6S SPE; Supelco). The flow
through fraction was made from the extract that came out from
the polyamide columns after crude WBM extract was loaded.
Fractions were eluted by a step gradient (50 ml of each step) of
increasing methanol to water. Flow through, the 0%, 20%, 40%,
60%, 80% and 100% methanol-water fractions were rotor-
evaporated to dryness and then redissolved in 6 ml of 50%
DMSO. Therefore, 60 g of WBM can produce 6 ml of each
fraction.
Placental microsomal aromatase assay
The aromatase assay was done by modification of a previous
method [10]. The substrate, [1-b-
3H] androstenedione, was
dissolved in serum-free cell culture medium. Placental micro-
somes were prepared as 0.1 g/L in a potassium phosphate buffer
(67 mM, pH 7.4) containing 20% glycerol, 0.5 mM dithiothre-
itol, and 0.25 M sucrose. The assay reaction mixture (225 ml),
containing placental microsomes (2.5 mg), [1-b-
3H] androstene-
dione (50 nM), progesterone (10 mM), and bovine serum
albumin (0.1%) in potassium phosphate (67 mM, pH 7.4), with
a sample solution in DMSO or H2O, was introduced in wells of a
96-well plate and preincubated at room temperature for 10
minutes; then, 25 ml of NADPH (3 mM) were added and the
mixture was incubated at 37uC for 15 minutes. The reaction was
terminated by addition of 50 ml of 20% trichloroacetic acid, and
250 ml of the reaction mixture was transferred to another well
containing the charcoal-dextran pellet. The solution was
thoroughly mixed and centrifuged (1,000 g, 5 minutes) to
remove non-reacted substrate; an aliquot of the supernatant
containing [
3H] H2O as reaction product was counted in a
Beckman Coulter LS 6500 Multi-Purpose Scintillation Counter.
This modified assay method allows us to carry out 96 assays at
the same time. Aromatase inhibition activity was calculated as
the percentage of remaining activity from the reaction without
WBM fractions. Analyses were carried out in triplicate and data
were expressed as the mean 6 SE.
Statistical analysis
For comparison of the 2 diets (HFD and HFD+WBM) used in
the in vivo experiment, a t-test was performed. The time-course
experiment (body weight) was analyzed by 2-factor ANOVA. For
multiple comparisons, analysis was followed by comparison of all
treatment groups with the control group (Dunnett’s test) or by
comparison of all pairs of treatment (Tukey’s test). Statistical
significance was defined as P,0.05. All data are expressed as
mean 6 standard error (SEM). Data sets were analyzed for
statistical significance using Prism GraphPad 4 software.
Results
WBM decreased liver weight and liver injury maker in
OVX mice
No significant differences in body weight were observed
between the control group fed the HFD and the group fed with
HFD+WBM in both the sham and the OVX groups (sham:
P=0.8972, OVX: P=0.0685) (Figure 1A and 1B). As expected,
liver weight increased in HFD-fed OVX mice compared to HFD-
Sham controls (P,0.01) and surprisingly, addition of WBM to the
HFD inhibited this increase (P,0.01) (Figure 1C). In addition,
serum ALT levels were higher in HFD-fed OVX mice than HFD-
fed sham mice (P,0.05); this increase was suppressed by WBM
(P,0.01) (Figure 1D). No significant differences in uterine weight
were observed between HFD and HFD+WBM in both groups
(Figure 1E).
Fat accumulation in the liver was decreased in OVX mice
after feeding mushroom diet
Pathological examination of liver tissue showed fewer fat
droplets (macrovesicular steatosis) in the cytoplasm of hepatocytes
in mice fed HFD+WBM compared to those of mice fed only HFD.
The fat droplets were concentrated in Zone III (near central veins)
(Figure 2A).
Increased insulin sensitivity in OVX mice fed with
mushroom diet
After 2 months on the WBM diet, a glucose tolerance test was
performed to evaluate circulating glucose concentration at each
time point. In sham mice, base-line glucose concentrations were
significantly lower in mice fed with HFD+WBM than mice with
HFD (P,0.05). In OVX groups, the base-line serum glucose levels
were not significantly different between mice with HFD and with
HFD+WBM. Compared to the sham operation group, OVX mice
showed higher serum glucose concentrations at 30 and 60 minutes
post glucose injection (P,0.01). OVX mice on the WBM diet had
improved glucose clearance at 60 minutes, compared to OVX
mice fed with HFD only (P,0.01) (Figure 2B).
Fatty acid biosynthesis pathways were down regulated in
livers from mice fed with WBM
To study the protective mechanisms of WBM, genes that were
regulated by the WBM diet in livers from OVX mice were
analyzed for their functional grouping using IPA. The data set
contained 20,234 unique genes. The top three networks of genes
significantly altered by WBM identified by IPA in our data set
are: (1) Small Molecule Biochemistry, Drug Metabolism, Lipid
Metabolism; (2) Lipid Metabolism, Nucleic Acid Metabolism,
Small Molecule Biochemistry; and (3) Organ Morphology,
Reproductive System Development and Function, Small Mole-
cule Biochemistry. Of these networks, two are involved in lipid
metabolism and of prime interest to this investigation of the
mouse liver phenotype: specifically, the levels of the genes
involved in fatty acid biosynthesis pathway were significantly
changed. The fatty acid biosynthesis pathway contains 7 genes, 4
of which passed our filter (Figure 3A). The Fisher’s exact test was
used to test whether the pathway of interest was over-represented
in the filtered gene list. The fatty acid biosynthesis pathway gave
a P-value of 1.05E-07, showing that this pathway was
significantly changed by WBM intake. Specific genes in this
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statistical significance by WBM are: Elovl6 (23.34-fold,
P,0.05), Fas (22.54-fold, P,0.05), Acc (22.37-fold, P,0.05)
and ATP citrate lyase (22.33 fold, P,0.05). The microarray
analysis results were validated by real time PCR using RNA
extracted from all treatment groups (sham, sham+WBM, OVX
and OVX+WBM). Increased Elovl6 expression was shown in
OVX mice fed with HFD compared to sham mice with HFD
(P,0.05). Fas expression was increased in OVX mice fed with
HFD compared to sham mice with HFD; however it did not
reach statistical significance. Results showed that addition of
WBM to the HFD significantly decreased Fas and Elovl6
expressions in the livers of OVX mice (P,0.05), which is in
agreement with the results of our microarray analysis (Figure 3B).
Figure 1. Effects of WBM feeding on body weight, liver weight, ALT serum levels and uterus weight. Seven-week old female C57B1/6J
mice were ovariectomized. These mice are a model of postmenopausal women (OVX, n=16). Control mice (sham, n=16) were subjected to sham
operation survival surgery. Both sham and OVX mice were fed a HFD (n=8/per group) or HFD with WBM (n=8/per group) diet for 3 months. Body
weight was measured once a week. (A) Body weight measurement of sham mice. (B) Body weight measurement of OVX mice. (C) Liver weight. (D)
ALT serum levels. (E) Uterus weight. Values are expressed as mean and standard error for 8 mice. * Statistical significance was defined as P,0.05.
doi:10.1371/journal.pone.0026654.g001
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expressions in HepG2 cells
To further define the effect of crude WBM extract, the
expression of FAS and ELOVL6 was measured in a human
hepatoma cell line, HepG2. FAS and ELOVL6 gene expressions
were significantly decreased in cells treated with WBM extract in a
dose dependent manner after 24 hours of treatment, in two doses
(1 and 5 ml/ml) (P,0.01). To confirm the results from HepG2
cells, we performed real time PCR to evaluate the levels of
ELOVL6 mRNA using another cell line, Huh7 cells. Huh7 is a well
differentiated hepatocyte derived cellular carcinoma cell line.
Since a similar degree of inhibition of ELOVL6 mRNA expression
was found in Huh7 cells by WBM extract compared to HepG2
cells (data not shown), we have performed additional experiments
using HepG2 cells. Treatment of the compound T0901317, which
is an agonist for LXR, increased the mRNA levels of these genes
significantly, compared to controls (P,0.01). T0901317-induced
FAS and ELOVL6 mRNA levels were decreased in the HepG2 cells
treated with WBM extract (5 ml/ml) (P,0.01) (Figure 4A). FAS
protein expression was also significantly decreased in the cells
treated with WBM extract (Figure 4B). Notably, the changes in
FAS and ELOVL6 mRNA expression paralleled the changes of
SREBP1c expression in HepG2 cell lines with each treatment
(Figure 4C).
Figure 2. WBM intake decreased fat accumulation in the liver and improved glucose clearance ability in OVX mice. (A) Macroscopic
appearance of liver from mice fed the HFD and HFD+WBM for 3 months in each sham and OVX group. The tissues were fixed with 10% formalin
overnight and then embedded in paraffin. Five-micrometer sections were cut and stained with hematoxylin and eosin, and examined by light
microscope. Representative H&E staining of livers from each group are shown. (B) Serum glucose concentration after glucose injection in mice fed
with HFD or HFD+WBM diet for 2 months. The mice were challenged with 1.5 mg glucose/g body weight glucose load. The glucose levels pre, 30, 60,
120 and 180 min post injection were measured using a glucometer. Values are expressed as mean and standard error for 8 mice. * Statistical
significance was defined as P,0.05.
doi:10.1371/journal.pone.0026654.g002
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After separation of WBM extract based on methanol concen-
tration, the expression of FAS and ELOVL6 genes was assayed by
real time PCR. We analyzed the data for each treatment by One-
way ANOVA, followed by comparison of all treatment groups
with the control group (Dunnett’s test). The FAS expression was
significantly inhibited (P,0.01) by all fractions, with the flow
through fraction providing the strongest inhibition, similar to that
of the crude fraction. Crude and flow through fractions
significantly inhibited ELOVL6 expression in HepG2 cells
compared to the control treatment (P,0.01). The 0% methanol
(= water fraction) and 40% methanol fractions had moderate
inhibitory effects (P,0.05) (Figure 5A). The inhibitory effect of
WBM extracts on aromatase activity was also evaluated. The flow
through fraction did not show any inhibition; however, the 20–
60% fractions provided the strongest inhibitory effect among all
Figure 3. Changes of lipid metabolism in the liver identified by microarray analysis and confirmed using real time PCR. (A) Raw
intensity measurements of all probe sets were corrected for the background, normalized and converted into transcript-level expression
measurements by using the IterPlier method in Affymetrix Power Tools. The number indicated the fold changes of the gene expression in OVX+WBM
compared to OVX. (B) Fas and Elovl6 mRNA expressions in liver tissues from mice of each treatment groups (Sham HFD, Sham HFD+WMB, OVX HFD
and OVX HFD+WBM) by real time PCR analysis. Gene expression was normalized with the b-actin housekeeping gene. Values are expressed as mean
and standard error for 8 mice. * Statistical significance was defined as P,0.05 between HFD vs HFD+WMB treatment in each group (sham or OVX).
doi:10.1371/journal.pone.0026654.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26654Figure 4. Changes in the mRNA and protein levels of genes related to fatty acid synthesis pathway in HepG2 cells treated with
WBM extract. Cells were incubated with vehicle control (Ethanol), T0901317 (10 mM) and/or WBM extract (1 and 5 ml/ml) for 24 hours for RNA and
48 hours for protein, respectively. (A) FAS and ELOVL6 mRNA levels. Gene expression was normalized with the b-actin housekeeping gene. (B) FAS
protein expressions were determined via western blotting. Bar graphs indicate quantification of three separate blots using Quantity One software.
Values are expressed as mean and standard error. (C) SREBP1 mRNA levels. We analyzed the data for each dose separately by ANOVA, followed by
Tukey’s multiple comparison test. Statistical significance was defined as * P,0.05 compared indicated treatment, a; P,0.05 compared to control, b;
P,0.05 compared to T0901317 treatment.
doi:10.1371/journal.pone.0026654.g004
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previous reports, which showed that the active ‘‘anti-aromatase’’
compound in this 20–60% fraction was conjugated linoleic acid
(CLA) [10]. While we have not yet identified the chemicals that
inhibit the fatty acid biosynthesis pathway, the current results
suggest that CLA is not the active component in the inhibition of
the fatty acid biosynthesis pathway in liver.
WBM extract modulates Liver X receptor (LXR) function
The IPA analysis showed that the canonical pathway for LXR/
RXR activation was significantly inhibited in the livers of OVX
mice fed with WBM (P=1.36E–02) compared to OVX mice fed
with HFD. To evaluate the direct effects of WBM extract on LXR
activation, an LXR-luciferase reporter assay was performed. The
LXR agonist T0901317 significantly increased the luciferase
activity in HepG2 cells transfected with the pCMX-VP16-hLXRa
and the LXR-responsive rCYP7A-DR-4x3-tk-LUC plasmid
(P,0.01). The LXR-luciferease activity was significantly decreased
when cells were treated T0901317 together with WBM extract in
a dose dependent manner (P,0.01). The WBM extract treatment
itself increased LXR-luciferase activity modestly, however this
increase was not significant (P.0.05) (Figure 6A). These results
suggest the presence of LXR antagonist(s) in the WBM extract.
Using an ER-positive MCF7 cell line, the ER-luciferase reporter
activity was significantly increased by treatment of E2 (P,0.01);
however, treatment with WBM extract did not affect ER-luciferase
activity (Figure 6B), indicating that the extract does not contain
estrogen-like chemicals and ER is not involved in the WBM-
mediated protection of the development of NAFLD.
Comparison of anti-NAFLD effects of various species of
mushroom
The extracts from enokitake mushroom, shiitake mushroom,
oyster mushroom, and WBM were tested for their ability to
suppress the fatty acid biosynthesis in HepG2 cells. Dose-
dependent inhibition of FAS and ELOVL6 gene expression was
found in all four mushroom species compared to untreated
controls (P,0.01). WBM showed greater inhibition of FAS
expression compared to oyster mushroom (P,0.05) but not to
other mushrooms at dose of 5 ml/ml; there were no significant
Figure 5. Effects of methanol fractions from WBM extract on FAS and ELOVL6 gene expressions and aromatase activity in HepG2
cells. Cells were incubated with each methanol fraction from WBM extract for 24 hours. (A) FAS and ELOVL6 gene expression was normalized with
the b-actin housekeeping gene. (B) Microsome assays were performed to evaluate anti-aromatase effects of WBM using the substrate, [1-b-
3H]
androstenedione. Activity was calculated to measure supernatant containing [
3H] H2O as reaction product, and then was counted in a Scintillation
Counter. Aromatase inhibition activity was calculated as the percentage of remaining activity from the reaction without mushroom fractions.
Analyses were carried out in triplicate and data were expressed as the mean 6 SE. We analyzed the data for each treatment by ANOVA, followed by
comparison of all treatment groups with the control group (Dunnett’s test). Statistical significance was defined as P,0.05.
doi:10.1371/journal.pone.0026654.g005
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and 2 ml/ml (Figure 7A). ELOVL6 expression was inhibited better
by the extracts of enokitake mushroom, oyster mushroom and
WBM compared to shiitake mushroom at the highest dose of 5 ml/
ml (P,0.05). At the low dose (1 ml/ml), WBM had the highest
inhibition (P,0.05) (Figure 7B).
Discussion
The results of this study suggest that WBM has a protective
effect against liver steatosis in the OVX mice, as a model for
postmenopausal women. The protective effect observed in our
mouse model with regard to liver steatosis was found to be
mediated though the suppression of fatty acid biosynthesis, as
indicated by our microarray data. In addition, WBM diet
improved insulin resistance observed in OVX mice fed with
HFD. Our finding is important since several papers have reported
that mushroom may have anti-atherogenic effects through
modulation of lipid profiles [12,17,18]. Although WBM is the
most common edible mushroom in the USA, to our knowledge,
this is the first study to show WBM has a protective effect against
liver steatosis in the mouse model of postmenopausal women.
Figure 6. LXR and ER activity in HepG2 cells treated with WBM extract. (A) HepG2 cells were transfected with the pCMX-VP16-hLXRa and
LXR-responsive rCYP7A-DR-4x3-tk-LUC, and following were incubated with vehicle control (ethanol), T0901317 (10 mM) and/or WBM extract (1, 2 and
5 ml/ml) and assayed for luciferase activity. (B) For evaluation of WBM effects on ER activity, HepG2 cells were transiently transfected with the pSG5-ER
and pGL3(ERE)3-Luc. 24 hours posttransfection, cells were treated with E2 (0.1 nM) or with WBM extract (5 and 10 ml/ml) for 24 hours. Data is
expressed as relative luciferase unit/protein content. Values are expressed as mean and standard error. For LXR activity, we analyzed the data for each
dose separately by ANOVA, followed by Tukey’s multiple comparison test. * P,0.05 compared indicated treatment, a; P,0.05 compared to T0901314
treatment. For ER activity, we analyzed the data for each treatment by ANOVA, followed by comparison of all treatment groups with the control
group (Dunnett’s test). Statistical significance was defined as P,0.05.
doi:10.1371/journal.pone.0026654.g006
Figure 7. Comparison of the effects of various species of mushroom on the fatty acid synthesis pathway. (A) FAS and (B) ELOVL6 gene
expressions in HepG2 cells treated with various species of mushroom extract (WBM, shiitake mushroom, enoki mushroom and oyster mushroom) for
24 hours. Real time PCR analysis was performed for the gene, ELOVL6 and FAS. Gene expression was normalized with the b-actin housekeeping gene.
Values are expressed as mean and standard error. We analyzed the data for each dose separately by ANOVA, followed by Tukey’s multiple
comparison test. Statistical significance was defined as P,0.05 compared to control.
doi:10.1371/journal.pone.0026654.g007
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than premenopausal women [19]. Aromatase knockout mice,
which are deficient in estrogen pathway, develop hepatic steatosis.
Moreover, hepatic steatosis was diminished in animals treated with
E2 [20]. Patients with a mutation of the aromatase gene showed
liver steatohepatitis, and estrogen treatment resulted in the
improvement of liver steatohepatitis [21]. These reports confirm
that estrogen has an important protective role against the
development of NAFLD. Tamoxifen is an antiestrogen used
widely in the treatment and chemoprevention of breast cancer.
Hepatic steatosis and non-alchoholic steatohepatitis have been
reported in patients treated with tamoxifen [22]. Therefore, fat
accumulation in liver is an important clinical concern in
postmenopausal women, especially those have anti-estrogenic
therapy. OVX mouse is the established model for postmenopausal
women. Studies in rodents showed that OVX promotes obesity
and its metabolic complication [4,15]. As a model of postmeno-
pausal women, our studies using OVX mice confirm a high fat diet
promotes liver steatosis, and a WBM-containing diet can alleviate
liver steatosis. The serum transaminase (ALT) level was measured,
as a sensitive method used in the detection of liver statosis in
clinical diagnosis [1]; it is also linked to liver fat content [23]. Our
results showed that serum ALT levels were significantly lowered in
OVX mice fed with WBM, to a similar level as in sham mice. It is
worthwhile to note that the WBM did not change mouse body
weight, but did have an impact on liver steatosis. This suggests that
WBM affects liver function specifically. Several rodent models
have shown that decreasing hepatic triglyceride pools correlates
with improved insulin sensitivity [1]. Also, several lines of evidence
suggest that lipid metabolites in the lipogenesis pathway in liver
are determinants for the development of insulin resistance [1].
Thus, we performed glucose resistance tests to evaluate glucose
clearance ability in OVX mice fed with WBM diet. Our data
showed that a WBM diet could improve steatosis-associated
insulin resistance in the OVX mice.
Our group previously reported that WBM extract inhibited
breast cancer cell growth in vitro and in vivo through inhibition of
the aromatase enzyme [10]. Our studies have revealed that the
chemicals that suppress fatty acid biosynthesis in liver are different
from those that inhibit aromatase activity. Furthermore, the WBM
extract does not have any estrogen-like activity, indicating that the
protective mechanism of WBM against liver steatosis is not
estrogen-mediated. Uterus weights were not changed in both sham
treated and OVX mice fed with WBM diet compared to those fed
with HFD only diet (Figure 1E). These results suggest that WBM
did not significantly change circulating estrogen levels in both
sham treated and OVX mice. Based on our current data, WBM
may have a beneficial effect on the liver in postmenopausal women
even at low estrogen conditions, particularly those women who are
under anti-estrogen therapy.
Microarray analysis revealed that multiple enzymes involved in
the fatty acid biosynthesis pathway were significantly down
regulated in the liver of OVX mice fed with a diet containing
WBM. Fas and Elovl6 were most down regulated by WBM
treatment. FAS plays an important role in the synthesis of fatty
acids via de novo lipogenesis. FAS catalyzes the last step in the fatty
acid biosynthetic pathway [1]. ELOVL6 is a rate-limiting enzyme
for the elongation of saturated and monounsaturated long chain
fatty acids. ELOVL6 is expressed in the liver and its mRNA levels
are up-regulated in obese animals [24]. Thus, researchers have
evaluated the therapeutic potential of ELOVL6 inhibitors for
metabolic disorders [25]. HepG2 is a human liver-derived
hepatoma cell line, and many liver-specific functions are
maintained in this cell line [26]. Since the expression of FAS
and ELOVL6 was decreased after WBM extract treatment in vitro
in the HepG2 cells, the active components in WBM are probably
not metabolites of biological conversion in an intact animal.
Moreover, multiple enzymes in the fatty acid biosynthesis pathway
are down-regulated by WBM extract, suggesting common
mechanisms may exist to regulate multiple enzymes. LXR has
been reported to control genes that encode proteins involved in de
novo lipogenesis, including FAS and ELOVL6. Moreover SREBP1c
is regulated through LXR [1]. Oral administration of the synthetic
LXR agonist, T0901317, to C57BL/6 mice resulted in increased
hepatic triglyceride levels, leading to liver steatosis [27]. Our
results showed that WBM extract down-regulated T0901317-
induced LXR receptor activity in the HepG2 cells, suggesting that
WBM extract mainly modulates LXR function in liver.
We also evaluated the effects of several types of mushrooms in
vitro using the HepG2 cells. All of the mushroom extracts showed a
dose-dependent inhibition of the expression of FAS and ELOVL6.
Although significant efforts have been made, we cannot yet
identify the phytochemicals that are responsible for the ‘‘anti-liver
steatosis’’ effect of mushrooms. Our previous report showed that
CLA is an active component with anti-aromatase activity (to
reduce estrogen) [10]. The CLA-containing fractions did not show
strong inhibition of ELOVL6 and FAS gene expression in HepG2
cells. Moreover, treatment with CLA did not decrease liver weight
and accumulation of fat in the livers of OVX mice [28]. These
results suggest that CLA is not the active component in the
inhibition of the fatty acid biosynthesis pathway in liver.
Phytosterols, such as oxysterols, have been found to be ligands
of LXR [29]. Ergosterol peroxide is an oxysterol that can be
produced by a hydrogen peroxide-dependent enzymatic oxidation
of ergosterol [30]. Ergosterol is an important sterol in WBM and is
shown to be a vitamin D2 precursor [31]. However, ergosterol was
not able to inhibit the expression of ELOVL6 and FAS in HepG2
cells in our in vitro studies (data not shown), suggesting that the
active chemical(s) may be another sterol or oxidized sterol.
In order to determine whether our results have a potential
application to women’s health, the human equivalent of doses used
in this study needs to be determined. The average WBM intake in
mouse studies is approximately 260 mg/day (average food intake
2.2g/day, WBM diet 120 g powder/kg diet). The human
equivalent dose (based on body surface area) [32] is equal to
42 g WBM powder for a 60 kg person. It is important to point out
that this would be a therapeutic dose to achieve the development
of NAFLD. This is a proof-of-concept study; therefore, the liver
protective effect could be achieved probably with lower levels of
WBM for women consuming a regular diet. Moreover, drug
discovery from natural products has been one of the main
approaches to develop new drugs. We are continuing our efforts in
the functional characterization of active components in WBM.
In summary, NAFLD is a widespread problem associated with
many metabolic disorders that has become increasingly prevalent
in our society. Postmenopausal women have the highest risk of
developing NAFLD, compared to premenopausal women and
men. The incidence would be even higher for those postmeno-
pausal women under anti-estrogen therapy and with a high BMI.
The pathogenesis of NAFLD is complicated and involves multiple
pathways. Single protein target drugs are not successful in the
treatment of NAFLD, and there is currently no generally accepted
therapeutic intervention for NAFLD. To date, the only effective
treatment of NAFLD is a general lifestyle change, including diet,
weight reduction and exercise. Our results showed that WBM
intake may be a viable dietary choice to prevent liver steatosis,
which is an early reversible stage of NAFLD in postmenopausal
women. WBM is widely available and inexpensive. If this effect
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PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e26654could be demonstrated in humans, postmenopausal women would
have a natural option for avoiding liver steatosis and its associated
conditions. This prevention of early stage of the disease leads to
reduce the risk of NAFLD. Furthermore, at the same time, WBM
would suppress aromatase to decrease risk of breast cancer.
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